Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Michelson's VivoSight moves into Japan

This article was originally published in Clinica

Executive Summary

UK imaging company Michelson Diagnostics has appointed Integral Corporation exclusive distributor of its recently CE-marked VivoSight scanner in Japan. Tokyo-based Integral will market and sell the system, which uses multi-Beam optical coherence tomography, for non-clinical use in cosmetic research settings. The VivoSight was CE marked in October for clinical use in Europe and non-clinical use worldwide. The scanner is designed to provide images of sub-surface tissue at a "far higher" resolution than other imaging modalities, according to Orpington-based Michelson. When positioned over tissue, the system's hand-held probe can capture either two- or three-dimensional images of a 5mm square region and highlight tissue microstructure features such as epidermis, dermis and sub-surface blood vessels.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel